Online inquiry

IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3428MR)

This product GTTS-WQ3428MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets HGF gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000601.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3082
UniProt ID P14210
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ3428MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7838MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GSK-1223249
GTTS-WQ14520MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SA-237
GTTS-WQ12711MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OMP-305B83
GTTS-WQ4089MR IVTScrip™ mRNA-Anti-IGF, BI 836(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BI 836
GTTS-WQ9373MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ15108MR IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SYD985
GTTS-WQ1987MR IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AGS-22CE
GTTS-WQ5387MR IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CD58-Fc
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW